For AML, Wilms’ Tumor-1 (WT-1) antigen was used to generate a well tolerable vaccine, which can induce the antigen-specific T cell responses and elicit a moderate but acceptable level of therapeutic responses [32]. The gene discussed is WT1; the disease is acute myeloid leukemia.